» Articles » PMID: 11413530

Patterns of Relapse of N2 Nonsmall-cell Lung Carcinoma Patients Treated with Preoperative Chemotherapy: Should Prophylactic Cranial Irradiation Be Reconsidered?

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2001 Jun 20
PMID 11413530
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although it induces a relevant reduction in the risk of both visceral metastases and locoregional recurrences, the combination of chemotherapy and surgery only marginally improves the survival of patients with Stage IIIA(N2) (International Union Against Cancer staging and classification system) nonsmall-cell lung carcinoma (NSCLC). The purpose of the current study was to analyze the patterns of relapse in these patients.

Methods: In this study, the authors compared the patterns of relapse in 81 patients with clinically detectable N2 NSCLC who had been treated with preoperative chemotherapy with the relapse patterns of 186 comparable patients who had been treated with primary surgery. Clinically detectable N2 (cN2) denotes mediastinal lymph node enlargement on computed tomography scan, which then is confirmed by mediastinoscopy.

Results: Overall 20% of patients developed a locoregional recurrence. Chemotherapy decreased the risk of visceral metastasis as 28% of the patients preoperatively treated and 38%of those not treated with preoperative chemotherapy presented a visceral metastasis (P < 0.05). Preoperative chemotherapy and adenocarcinoma subtypes were associated with a higher rate of brain metastasis (P < 0.05). Thirty-two percent of the patients treated preoperatively and 18% of those not treated with preoperative chemotherapy presented a brain metastasis (P < 0.05), which was isolated in 22% and 11% of the patients, respectively (P < 0.05).

Conclusion: The current study found that preoperative chemotherapy for cN2 decreases the risk of visceral metastasis but is associated with a high rate of isolated brain metastases. Prophylactic cranial irradiation may need to be reinvestigated in clinical trials, especially in patients who present with an adenocarcinoma.

Citing Articles

Comprehensive Analysis of Lung Adenocarcinoma and Brain Metastasis through Integrated Single-Cell Transcriptomics.

Souza V, Telkar N, Lam W, Reis P Int J Mol Sci. 2024; 25(7).

PMID: 38612588 PMC: 11012108. DOI: 10.3390/ijms25073779.


A "Seed-and-Soil" Radiomics Model Predicts Brain Metastasis Development in Lung Cancer: Implications for Risk-Stratified Prophylactic Cranial Irradiation.

Chu X, Gong J, Yang X, Ni J, Gu Y, Zhu Z Cancers (Basel). 2023; 15(1).

PMID: 36612303 PMC: 9818608. DOI: 10.3390/cancers15010307.


Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies.

Mikolajewicz N, Khan S, Trifoi M, Skakdoub A, Ignatchenko V, Mansouri S Neurooncol Adv. 2022; 4(1):vdac161.

PMID: 36382110 PMC: 9639356. DOI: 10.1093/noajnl/vdac161.


[Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer].

Sun S, Men Y, Hui Z Zhongguo Fei Ai Za Zhi. 2022; 25(3):193-200.

PMID: 35340162 PMC: 8976204. DOI: 10.3779/j.issn.1009-3419.2022.101.08.


Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.

Varlotto J, Wang Y, Sun Z, Wakelee H, Ramalingam S, Schiller J JTO Clin Res Rep. 2022; 3(3):100274.

PMID: 35281954 PMC: 8908250. DOI: 10.1016/j.jtocrr.2021.100274.